181 related articles for article (PubMed ID: 8950524)
1. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
Coque TM; Singh KV; Murray BE
J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children.
McNeeley DF; Eckert SJ; Noel GJ
Pediatr Infect Dis J; 2000 Jul; 19(7):675-6. PubMed ID: 10917238
[No Abstract] [Full Text] [Related]
7. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Jones RN; Beach ML; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
11. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden.
Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T; Kronvall G
Scand J Infect Dis; 1999; 31(6):567-72. PubMed ID: 10680987
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.
Urbásková P; Trupl J; Hupková H; Appelbaum PC; Jacobs MR
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):686-8. PubMed ID: 8894582
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
Jones RN; Barrett MS; Deguchi T
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
18. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.
Evans ME; Titlow WB
Antimicrob Agents Chemother; 1998 Mar; 42(3):727. PubMed ID: 9517965
[No Abstract] [Full Text] [Related]
19. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Zinner SH; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
Fitzgibbon JE; John JF; Delucia JL; Dubin DT
Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
